Definium Therapeutics Presents Phase 3 DT120 Data at NEI Congress

Definium Therapeutics presented topline Phase 3 data for DT120 ODT in generalized anxiety disorder and major depressive disorder. The body says the presentation covered the clinical program but is truncated before further details.